LivaNova (NASDAQ:LIVN) Raised to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a report published on Wednesday morning.

LIVN has been the topic of several other reports. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. Robert W. Baird lifted their target price on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Mizuho cut their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, LivaNova has an average rating of “Buy” and an average target price of $69.17.

LivaNova Stock Performance

Shares of LivaNova stock opened at $47.63 on Wednesday. LivaNova has a 1 year low of $43.15 and a 1 year high of $64.47. The company’s fifty day simple moving average is $49.74 and its 200-day simple moving average is $50.20. The company has a market cap of $2.59 billion, a price-to-earnings ratio of 113.40 and a beta of 0.98. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Insider Activity

In related news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Several institutional investors have recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. bought a new stake in LivaNova during the fourth quarter worth about $1,954,000. Diversified Trust Co grew its position in LivaNova by 9.5% during the 4th quarter. Diversified Trust Co now owns 16,432 shares of the company’s stock worth $761,000 after acquiring an additional 1,425 shares during the last quarter. Nordea Investment Management AB increased its holdings in LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock valued at $3,188,000 after purchasing an additional 12,470 shares in the last quarter. Central Pacific Bank Trust Division raised its position in LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after purchasing an additional 720 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in shares of LivaNova during the third quarter worth $219,000. 97.64% of the stock is owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.